文献速递眼底病与葡萄膜炎

Pegcetacoplan治疗的地图样萎缩患者视力与生活质量结局:OAKS与DERBY试验的事后分析

Visual Acuity and Quality of Life Outcomes With Pegcetacoplan Treatment: A Post Hoc Analysis From the OAKS and DERBY Trials.
PubMed 文献 · Am J Ophthalmol · 2025-05-29

基于OAKS和DERBY两项24个月3期随机双盲假对照试验的事后分析纳入888例地图样萎缩患者,按萎缩灶距中心凹≥250 µm(n=192)或<250 µm(n=696)分层。距中心凹≥250 µm组接受pegcetacoplan治疗眼在24个月时视力下降方向性更慢(均值+5.6,SE 3.2,P=.0785)、生活质量下降方向性更慢(均值+4.0,SE 2.4,P=.0905),与假对照眼相比;距中心凹<250 µm组视力变化(均值-1.6,SE 1.1,P=.1522)和生活质量变化(-2.3,SE 1.1,P=.0284)在变异范围内。

要点

  • 距中心凹≥250 µm的萎缩灶接受pegcetacoplan治疗眼24个月视力下降较假对照眼方向性更慢(均值+5.6,P=.0785)。
  • 距中心凹≥250 µm组生活质量下降较假对照眼方向性更慢(均值+4.0,P=.0905)。
  • 距中心凹<250 µm组视力与生活质量变化均在变异范围内(视力P=.1522,生活质量P=.0284)。

核心结论

  • Pegcetacoplan治疗对萎缩灶距中心凹≥250 µm的地图样萎缩患者可能带来有意义的视力与生活质量下降减缓。
  • 萎缩灶距中心凹<250 µm患者接受pegcetacoplan治疗后视力与生活质量变化在变异范围内。

研究设计与样本

  • OAKS与DERBY两项全球、24个月、多中心、随机、双盲、假对照3期研究的事后分析,评估pegcetacoplan治疗年龄相关性黄斑变性所致地图样萎缩。
  • 纳入888例地图样萎缩患者,按OCT测量的萎缩灶距中心凹≥250 µm(n=192)或<250 µm(n=696)分层。
  • 在基线和第24个月评估最佳矫正视力(BCVA),每4个月评估一次;在基线和第24个月评估25项美国国立眼科研究所视功能问卷(NEI VFQ-25),每6个月评估一次。
  • 采用倾向评分加权进行调整,模型设定和基线协变量选择基于临床理由预先指定。

主要发现

  • 距中心凹≥250 µm组pegcetacoplan治疗眼24个月视力较基线变化均值+5.6(SE 3.2,P=.0785),与假对照眼相比方向性更慢。
  • 距中心凹≥250 µm组pegcetacoplan治疗眼24个月生活质量较基线变化均值+4.0(SE 2.4,P=.0905),与假对照眼相比方向性更慢。
  • 距中心凹<250 µm组pegcetacoplan治疗眼24个月视力较基线变化均值-1.6(SE 1.1,P=.1522),与假对照眼相比在变异范围内。
  • 距中心凹<250 µm组pegcetacoplan治疗眼24个月生活质量较基线变化-2.3(SE 1.1,P=.0284),与假对照眼相比在变异范围内。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effect of pegcetacoplan on visual function and patient quality of life (QoL) measures based on distance of geographic atrophy (GA) lesions from the center of the fovea. DESIGN: Post hoc analysis from OAKS and DERBY, two global, 24-month, multicenter, randomized, double-masked, sham-controlled phase 3 studies evaluating pegcetacoplan treatment for GA in age-related macular degeneration (AMD). PARTICIPANTS: 888 study patients with GA for whom all data necessary for the post hoc analysis to be performed had been collected were included. METHODS: Best-corrected visual acuity (BCVA) and 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) were assessed at baseline and every 4 and 6 months, respectively, to completion at month 24 in both pegcetacoplan-treated eyes and sham (observed) eyes. Eyes were stratified based on optical coherence tomography‒derived GA lesion location ≥250 µm (n = 192) or <250 µm (n = 696) from the foveal center. MAIN OUTCOME MEASURES: Change from baseline in BCVA and NEI VFQ-25 was evaluated over 24 months in GA lesions based on distance (≥250 or <250 µm) from the foveal center. Adjustment was conducted via propensity score weighting, where model specification and baseline covariate selection were done a priori based on clinical rationale. RESULTS: Pegcetacoplan-treated eyes with GA lesion margins ≥250 µm from the foveal center demonstrated directionally slower decline in visual acuity (mean +5.6 [SE 3.2] [P = .0785]) and QoL (mean +4.0 [SE 2.4] [P = .0905]) from baseline at 24 months compared with sham. The change in visual acuity (BCVA, mean -1.6 [SE 1.1] [P = .1522]) and QoL (NEI VFQ-25, -2.3 [1.1] [P = .0284]) in pegcetacoplan-treated eyes with GA lesion margins <250 µm from the foveal center were within the limits of variability compared with sham. CONCLUSIONS: Pegcetacoplan treatment demonstrated a potentially meaningful slower decline in visual acuity and QoL for patients with GA lesions ≥250 µm from the foveal center. The change in visual acuity and QoL seen with pegcetacoplan treatment for patients with GA lesions <250 µm from the foveal center were within the limits of variability.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Chiang A, Davis M, Stevens W, et al. Visual Acuity and Quality of Life Outcomes With Pegcetacoplan Treatment: A Post Hoc Analysis From the OAKS and DERBY Trials. Am J Ophthalmol. 2025. PMID: 40449644. doi:10.1016/j.ajo.2025.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。